Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cotadutide QTc evaluation in healthy participants
NCT05668936Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cotadutide in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by AstraZeneca. Primary endpoint: Time-matched change-from-baseline Fridericia's correction of QT interval. Started Jan 2023; status: terminated.
02
Drugs
cotadutide
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05668936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668936.